ライフサイエンスコーパス: nervous system tumor

1 gnant meningiomas are a rare type of central nervous system tumor.

2 Meningiomas are the most common primary nervous system tumor.

3 and cellular pathogenesis of NF1-associated nervous system tumors.

4 g, and determining the prognosis for central nervous system tumors.

5 aches with radioligand therapies for central nervous system tumors.

6 that causes development of multiple types of nervous system tumors.

7 n the development and progression of central nervous system tumors.

8 nscriptional regulation in pediatric central nervous system tumors.

9 al in neurodegenerative diseases and central nervous system tumors.

10 pruritus is a rare manifestation of central nervous system tumors.

11 ost common and deadly of the primary central nervous system tumors.

12 mors, representing 15% to 25% of all central nervous system tumors.

13 nting for approximately one-fifth of central nervous system tumors.

14 r benefit in patients with malignant central nervous system tumors.

15 genetic changes in the evolution of central nervous system tumors.

16 for malignant rhabdoid and childhood central nervous system tumors.

17 inked to increased aggressiveness in several nervous system tumors.

18 inhibiting prosurvival mechanisms in central nervous system tumors.

19 evaluate the incidence of MSI in 206 central nervous system tumors.

20 ma is one of the most deadly primary central nervous system tumors.

21 d to the development of benign and malignant nervous system tumors.

22 in human gynecological, breast, and central nervous system tumors.

23 on and acquired genetic mutations in central nervous system tumors.

24 biology and management of pediatric central nervous system tumors.

25 romes are associated with the development of nervous system tumors.

26 te individuals), cause of death (eg, central nervous system tumor, 0.48 [SE, 0.08]; P < .001; vs anox

27 recursor [BCP] ALL), 44 (13.3%) with central nervous system tumors, 80 (24.1%) with solid tumors, and

28 CI, 0.39-0.99), but not with risk of central nervous system tumors (AHR, 0.96; 95% CI, 0.51-1.88) or

29 ningioma patients, compared to other central nervous system tumor and non-tumor entities.

30 s represent approximately 30% of all central nervous system tumors and 80% of malignant brain tumors.

31 aracterized by multiple benign and malignant nervous system tumors and cognitive deficits.

32 oss of Merlin, patients suffer from multiple nervous system tumors and die on average around age 40.

33 ive hematological malignancies, four central nervous system tumors and eight solid tumors).

34 uated primary human NF1-deficient peripheral nervous system tumors and found that MNKs are activated

35 vances in defining the molecular etiology of nervous system tumors and learning disabilities.

36 Malignant gliomas are central nervous system tumors and remain among the most treatmen

37 stic leukemia, Hodgkin lymphoma, and central nervous system tumors) and across chronological age grou

38 as constitute the second most common central nervous system tumor, and yet relatively little is known

39 aracterized by multiple benign and malignant nervous system tumors, and by learning defects in 45% of

40 re human hereditary neuropathies, peripheral nervous system tumors, and common degenerative diseases.

41 FI) is a common genetic disorder that causes nervous system tumors, and learning and memory defects i

42 Nervous system tumors are clinically challenging neoplas

43 onstrate that VHL disease-associated central nervous system tumors are composed of developmentally ar

44 Although analogous studies of rare nervous system tumors are needed, there are major barrie

45 Pediatric solid and central nervous system tumors are the leading cause of cancer-re

46 Peripheral sympathetic nervous system tumors are the most common extracranial s

47 Primary central nervous system tumors are the second most common form of

48 ghly expressed in a panel of cell lines from nervous system tumors arising from glia, although expres

49 ingiomas are the most common primary central nervous system tumors, arising from arachnoid cap cells

50 uman neurofibromas, schwannomas, and various nervous system tumors associated with NF1 or NF2; midkin

51 ndrome in which affected individuals develop nervous system tumors at an increased frequency.

52 As treatment with chemotherapy for central nervous system tumors becomes more successful, new measu

53 e among patients without significant central nervous system tumor burden and to describe the experime

54 ly in familial schwannomas and other central nervous system tumors, but also in malignant tumors unre

55 In both breast cancers and central nervous system tumors, cancer cells differ in their abil

56 Central nervous system tumors carry grave clinical prognoses due

57 The methionine-dependent central nervous system tumor cell lines DAOY (medulloblastoma),

58 ession was low or absent in nonglial-derived nervous system tumor cell lines.

59 The 2021 World Health Organization central nervous system tumor classification is a major advance t

60 ty has been established in pediatric central nervous system tumors, epigenomic alterations at the cel

61 he TSC2 gene, seen in both renal and central nervous system tumors from TSC patients?

62 However, little is known about how central nervous system tumors guard against immune eradication.

63 as induction of humoral responses by central nervous system tumors has been reported to be minimal, w

64 Central nervous system tumors have resisted effective chemothera

65 iencing CRCI, including survivors of central nervous system tumors, Hodgkin lymphoma, testicular, and

66 tumor suppressor found to be mutated in most nervous system tumors; however, it is not mutated in gli

67 Meningiomas are common central nervous system tumors; however, the mechanisms underlyin

68 Meningiomas are common central nervous system tumors; however, the molecular mechanisms

69 une responses against peripheral and central nervous system tumors; however, variable results on the

70 cancer is medulloblastoma, a common central nervous system tumor in children.

71 (GBM), the most common and malignant central nervous system tumor in humans, is highly proliferative

72 One-third of all primary central nervous system tumors in adults are meningiomas.

73 meningiomas, one of the most common central nervous system tumors in humans.

74 port that 14% of ptc+/- mice develop central nervous system tumors in the posterior fossa by 10 month

75 ned and novel approaches to modeling central nervous system tumors, including gliomas, meningiomas, m

76 matosis 1 (NF1), are prone to development of nervous system tumors, including neurofibromas and piloc

77 ome are prone to the development of multiple nervous system tumors, including optic pathway gliomas (

78 ion syndrome are prone to the development of nervous system tumors, including schwannomas and meningi

79 vation results in the development of central nervous system tumors, including schwannomas, meningioma

80 ndrome in which affected individuals develop nervous system tumors, including schwannomas, meningioma

81 detected in normal brain, malignant central nervous system tumors, including tumors metastatic to th

82 Glioblastoma is the most common central nervous system tumor, is associated with high morbidity

83 ess the role of N-myc in neurogenesis and in nervous system tumors, it was conditionally disrupted in

84 diagnostic type (with patients with central nervous system tumors least likely to visit).

85 ell growth, especially against human central nervous system tumor lines such as SF-295 cells.

86 red to astrocytomas, the most common central nervous system tumor, little is known about the molecula

87 Although meningiomas are common central nervous system tumors, little is known about the genetic

88 , -4.0 to 24.2] per 100 000) and sympathetic nervous system tumors (<5 cancer cases; hazard ratio, 7.

89 ns in gene expression found in human central nervous system tumors may actually contribute to the eti

90 In 76 central nervous system tumors, methylome analysis confirmed diag

91 Malignant glioma is the most common central nervous system tumor of adults and is associated with a

92 involving >2400 pediatric brain and central nervous system tumors of diverse histologies from the Ch

93 ed not only in schwannomas and other central nervous system tumors of NF2 patients but also in their

94 l age increased risk of leukemia and central nervous system tumors, older paternal age was not associ

95 (OR, 2.1; 95% CI, 1.8-2.5; P<.001), central nervous system tumors (OR, 1.7; 95% CI, 1.5-2.0; P<.001)

96 emia, neuroblastoma, retinoblastoma, central nervous system tumors, or renal or germ-cell tumors.

97 With the exception of primary central nervous system tumors, organ recovery is no longer consi

98 Childhood primary central nervous system tumors remain a therapeutic conundrum.

99 Nervous system tumors represent unique neoplasms that ar

100 t associated with the peripheral and central nervous system tumors seen in NF1.

101 nd oligodendrogliomas, as well as peripheral nervous system tumors such as neurofibromas, schwannomas

102 8), human melanoma (RPMI), and human central nervous system tumor (TE671) cells.

103 Neuroblastoma is a peripheral nervous system tumor that accounts for 8-10% of all soli

104 em gliomas (BSG) are a rare group of central nervous system tumors that arise mostly in children and

105 Meningiomas are central nervous system tumors that originate from the meningeal

106 Ependymomas are aggressive central nervous system tumors that resist chemotherapy.

107 Analysis of a central nervous system tumor tissue microarray revealed that str

108 uman Cancer Consortium convened a meeting on Nervous System Tumors to review recent advances and sugg

109 , which apply broadly to many or all central nervous system tumor types, as well as the addition, eli

110 Focusing on nervous system tumors, we describe the normal relationsh

111 cytosine modifications in pediatric central nervous system tumors, we utilize a multi-omic approach

112 melanomas, and radiotherapy-related central nervous system tumors, which are associated with excess

113 Meningiomas are common nervous system tumors, whose molecular pathogenesis is p

114 Glioblastoma (GBM) is an aggressive central nervous system tumor with a poor prognosis.

115 rade III spinal ependymomas are rare central nervous system tumors with poor prognoses and limited tr

116 ndymoma is a heterogeneous entity of central nervous system tumors with well-established molecular gr

117 an effective antitumor agent for non-central nervous system tumor xenografts with an excellent safety